Clinical Trial Update: Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a recombinant tissue-type plasminogen activator derivative (rPA) in acute pulmonary embolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• recombinant human tissue-type plasminogen activator derivative (rPA)

Snippet

Sponsor: Angde Biotech Pharmaceutical Co., Ltd. | Conditions: Acute Pulmonary Embolism | Phase 2 | Status: UNKNOWN